lists some of the many beta blockers which are currently available, illustrating the selection problem facing clinicians. One differentiating feature is that some of these compounds are selective on the cardiac beta receptors leaving the peripheral beta2 receptors relatively untouched and it is these that will be reviewed in this paper, with particular emphasis on atenolol (Fig 1) .
In addition to cardioselectivity, beta-blocking drugs possess other properties which may be of importance in clinical practice, and Table 2 shows certain features of propranolol, oxprenolol, practolol and the D-isomer of propranolol. They are all beta-blocking drugs but they may or may not have these additional features: membrane stabilizing effect (MSA); local anesthetic effect; and partial agonist effect, i.e. intrinsic sympathomimetic activity (ISA).
Atenolol, by comparison, has a different profile from the agents which have been previously used. It is a cardioselective beta-blocking drug, which is without membrane stabilizing or partial agonist activity. So there are at least 
Specificity
Experimental laboratory work has shown atenolol to be a specific beta-blocking drug. Fig 2 shows the results of a study conducted by Conway et al. (1976) on the effect on cardiac contractility of various agents, calcium, isoprenaline stimulating the beta receptors, glucagon and acetylstrophanthidin. It is clear that the increase in cardiac contractility which would be expected with isoprenaline is completely blocked by prior administration of atenolol, whereas the effects of calcium, glucagon and strophanthidin are left completely untouched. This is evidence that atenolol is a specific beta-receptor antagonist. It is interesting and valuable for the clinician to know that this effect can be overcome by cardiac glycosides.
Potency
The isoprenaline dose-response curve using incremental i.v. boluses of isoprenaline illustrates the increase in heart rate in the untreated subject (Fig 3) . If the drug under study is a competitive inhibitor then there would be a parallel shift to the right when it is given and this is clearly shown with increasing oral doses of atenolol. The blood concentrations were taken at the time when the curve was completed, which was around 15 to 20 minutes. The higher blood levels were associated with a greater shift to the right, as would be expected. As far as the clinician is concerned, this is particularly interesting, because these blood levels are in the range that may be expected following oral therapy. Control, 0-0; -25Smg; *--75mg;
A-A 150 mg. Blood concentr-ations are shown in parentheses Another marker used in assessing beta blockade is suppression of the maximum post-exercise tachycardia. If the subjects are exercised to the maximum tolerance the inhibitor tone of the vagus is reduced and what is left is purely a sympathetic drive. Fig 4 shows some work done by Professor Shanks in Belfast, looking at the relationship between the suppression of the tachycardia and the blood level following an oral dose of 100 mg atenolol. These follow each other fairly closely and the maximum reduction is around 40% of the pretreatment level. This suppression of pulse rate at maximum exercise is another clear indication that this compound is a beta-blocking drug, and the degree of reduction seems to be related to the circulating blood levels. This fact has been confirmed by a multicentre trial ( Fig 5) using pooled data on the suppression of maximum exercise tachycardia and atenolol blood levels. Again there is a relationship between the dose circulating and the percent reduction in the tachycardia. It is suggested that a blood level of 2 jug/ml is maximal as far as suppression of tachycardia is concerned, and that further increases in blood level do not produce a further decrease in exercise-induced tachycardia. The experimental work on the shift of dose-response curves would suggest that weight for weight in molar concentrations, atenolol is equipotent to propranolol.
Selectivity
In animal work the effect of isoprenaline on uterine relaxation is not blocked by atenolol. Histamine produces bronchospasm in the experimental animal but not if they are pretreated with isoprenaline and that protective element is not lost when they have been pretreated with atenolol. There is clear laboratory evidence that this is a selective beta-blocking drug.
Conway et al. (1976) have infused isoprenaline into human volunteers to reach a steady state and they have then looked at the effect on the diastolic blood pressure, which will tend to fall due to the beta2 stimulant effect (Fig 6) . When propranolol is given there is a marked shift to the right as the peripheral beta2 receptors are blocked, but with atenolol the shift to the right is not nearly so marked. Looking at the blood concentration there is a ten-fold difference, so the shift to the right is less impressive. Dr P Turner has looked at airways peak flow over a 24-hour period in patients who received 200 mg atenolol orally. At rest there was no statistical difference in the change in the peak flow rate. However, on exercise, when the sympathetic system plays a part in producing dilatation of the airways, there was a reduction of between 20 and 30 % in PFR. Practolol had no effect, propranolol had an even greater effect, and atenolol fell halfway between these two, so although it is selective it is possibly only partially so.
The plasma elimination half-life of atenolol following a dose of 200 mg is six hours in normal healthy subjects. Fig 7 is from work by Brown et al. in Belfast and shows that after administration for eight days there is no change in half-life. Other workers have found that in the presence of renal failure the half-life of atenolol is increased and, with severe renal impairment, can go up to 48 hours; the dose will therefore need to be reduced.
Atenolol is poorly absorbed and only about 10 % of what is absorbed is metabolized. That 10% forms a glucuronide and a hydroxylated compound and between 40 and 50 % of the unchanged compound is recovered in the urine. Following an i.v. dose without the absorption problem, there is obviously greater urinary recovery (Fig 8) . Therefore, in the presence of renal failure, there is no evidence that there is an alternative biliary route for metabolism and excretion, and the dosage must be reduced.
Atenolol has possible theoretical advantages such as cardioselectivity which may mean that it is safer in patients with respiratory disease. It also does not have intrinsic sympathomimetric activity but is that important? As there is very little peripheral effect, what effect is there on plasma renin? Is the recovery following hypoglycamia delayed? These are some of the questions that need answers and which may well be answered in subsequent papers.
